Publication:
FCERI and Histamine Metabolism Gene Variability in Selective Responders to NSAIDS.

dc.contributor.authorAmo, Gemma
dc.contributor.authorCornejo-Garcia, Jose A
dc.contributor.authorGarcia-Menaya, Jesus M
dc.contributor.authorCordobes, Concepcion
dc.contributor.authorTorres, M J
dc.contributor.authorEsguevillas, Gara
dc.contributor.authorMayorga, Cristobalina
dc.contributor.authorMartinez, Carmen
dc.contributor.authorBlanca-Lopez, Natalia
dc.contributor.authorCanto, Gabriela
dc.contributor.authorRamos, Alfonso
dc.contributor.authorBlanca, Miguel
dc.contributor.authorAgundez, Jose A G
dc.contributor.authorGarcia-Martin, Elena
dc.contributor.authoraffiliation[Amo,G; Esguevillas,G; Martínez,C; Agúndez,JAG; García-Martín,E] Departamento de Farmacología, Universidad de Extremadura, Cáceres, Spain. [Cornejo,JA; Mayorga,C] Laboratorio de Investigación, Instituto de Investigación Biomédica de Málaga, Hospital Regional Universitario de Málaga, Universidad de Málaga, Málaga, Spain. [García-Menaya,JM; Cordobes,C] Servicio de Alergologia, Hospital Infanta Cristina, Badajoz, Spain. [Torres,MJ] UGC de Alergia, Instituto de Investigación Biomédica de Málaga, Hospital Regional Universitario de Málaga, Universidad de Málaga, Málaga, Spain. [Blanca-Lopez,N; Canto,G; Blanca,M] Servicio de Alergologia, Hospital Infanta Leonor, Madrid, Spain. [Ramos,A] Departamento de Matemáticas, Universidad de Extremadura, Cáceres, Spain.es
dc.contributor.funderFEDER funds from the European Union
dc.contributor.funderFondo de Investigación Sanitaria, Instituto de Salud Carlos III, Spain
dc.contributor.funderJunta de Extremadura, Spain
dc.date.accessioned2016-11-11T09:18:24Z
dc.date.available2016-11-11T09:18:24Z
dc.date.issued2016-09-29
dc.description.abstractThe high-affinity IgE receptor (Fcε RI) is a heterotetramer of three subunits: Fcε RIα, Fcε RIβ, and Fcε RIγ (αβγ2) encoded by three genes designated as FCER1A, FCER1B (MS4A2), and FCER1G, respectively. Recent evidence points to FCERI gene variability as a relevant factor in the risk of developing allergic diseases. Because Fcε RI plays a key role in the events downstream of the triggering factors in immunological response, we hypothesized that FCERI gene variants might be related with the risk of, or with the clinical response to, selective (IgE mediated) non-steroidal anti-inflammatory (NSAID) hypersensitivity. From a cohort of 314 patients suffering from selective hypersensitivity to metamizole, ibuprofen, diclofenac, paracetamol, acetylsalicylic acid (ASA), propifenazone, naproxen, ketoprofen, dexketoprofen, etofenamate, aceclofenac, etoricoxib, dexibuprofen, indomethacin, oxyphenylbutazone, or piroxicam, and 585 unrelated healthy controls that tolerated these NSAIDs, we analyzed the putative effects of the FCERI SNPs FCER1A rs2494262, rs2427837, and rs2251746; FCER1B rs1441586, rs569108, and rs512555; FCER1G rs11587213, rs2070901, and rs11421. Furthermore, in order to identify additional genetic markers which might be associated with the risk of developing selective NSAID hypersensitivity, or which may modify the putative association of FCERI gene variations with risk, we analyzed polymorphisms known to affect histamine synthesis or metabolism, such as rs17740607, rs2073440, rs1801105, rs2052129, rs10156191, rs1049742, and rs1049793 in the HDC, HNMT, and DAO genes. No major genetic associations with risk or with clinical presentation, and no gene-gene interactions, or gene-phenotype interactions (including age, gender, IgE concentration, antecedents of atopy, culprit drug, or clinical presentation) were identified in patients. However, logistic regression analyses indicated that the presence of antecedents of atopy and the DAO SNP rs2052129 (GG) were strongly related (P < 0.001 and P = 0.005, respectively) with selective hypersensitivity to ibuprofen. With regard to patients with selective hypersensitivity to ASA, men were more prone to develop such a reaction than women (P = 0.011), and the detrimental DAO SNP rs10156191 in homozygosity increased the risk of developing such hypersensitivity (P = 0.039).es
dc.description.sponsorshipThis study was financed by grants PI12/00241, PI12/00324, PI15/00303, RETICS RD12/0013/0002, and RETICS RD16/0006/0004 from Fondo de Investigación Sanitaria, Instituto de Salud Carlos III, Spain, and GR15026 from Junta de Extremadura, Spain. Financed in part with FEDER funds from the European Union.
dc.description.versionYeses
dc.identifier.citationAmo G, Cornejo-García JA, García-Menaya JM, Cordobes C, Torres MJ, Esguevillas G, et al. FCERI and Histamine Metabolism Gene Variability in Selective Responders to NSAIDS. Front Pharmacol. 2016; 7:353es
dc.identifier.doi10.3389/fphar.2016.00353
dc.identifier.essn1663-9812
dc.identifier.pmcPMC5040715
dc.identifier.pmid27746735
dc.identifier.urihttp://hdl.handle.net/10668/2511
dc.journal.titleFrontiers in Pharmacology
dc.language.isoen
dc.page.number9
dc.provenanceRealizada la curación de contenido 02/04/2025
dc.publisherFrontiers Research Foundationes
dc.relation.projectIDPI12/00241
dc.relation.projectIDPI12/00324
dc.relation.projectIDPI15/00303
dc.relation.projectIDRD12/0013/0002
dc.relation.projectIDRD16/0006/0004
dc.relation.projectIDGR15026
dc.relation.publisherversionhttp://journal.frontiersin.org/article/10.3389/fphar.2016.00353/full#h1es
dc.rightsAttribution 4.0 International
dc.rights.accessRightsopen access
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.subjectFcεes
dc.subjectRIes
dc.subjectHistaminees
dc.subjectNon-steroidal anti-inflammatory drugs (NSAIDS)es
dc.subjectHypersensitivity drug reactionses
dc.subjectBiomarkerses
dc.subjectAcetaminofénes
dc.subjectAntiinflamatorios no Esteroideoses
dc.subjectAspirinaes
dc.subjectDiclofenacoes
dc.subjectDipironaes
dc.subjectÁcido flufenámicoes
dc.subjectMarcadores genéticoses
dc.subject.decsHistamina
dc.subject.decsIbuprofeno
dc.subject.decsInmunoglobulina E
dc.subject.decsIndometacina
dc.subject.decsCetoprofeno
dc.subject.decsPiroxicam
dc.subject.decsPolimorfismo de Nucleótido Simple
dc.subject.decsPiridinas
dc.subject.decsReceptores de IgE
dc.subject.decsSulfonas
dc.subject.meshMedical Subject Headings::Chemicals and Drugs::Organic Chemicals::Amides::Anilides::Acetanilides::Acetaminophenes
dc.subject.meshMedical Subject Headings::Chemicals and Drugs::Chemical Actions and Uses::Pharmacologic Actions::Physiological Effects of Drugs::Peripheral Nervous System Agents::Sensory System Agents::Analgesics::Analgesics, Non-Narcotic::Anti-Inflammatory Agents, Non-Steroidales
dc.subject.meshMedical Subject Headings::Chemicals and Drugs::Organic Chemicals::Carboxylic Acids::Acids, Carbocyclic::Benzoic Acids::Hydroxybenzoic Acids::Salicylic Acids::Aspirines
dc.subject.meshMedical Subject Headings::Chemicals and Drugs::Organic Chemicals::Carboxylic Acids::Acids, Carbocyclic::Phenylacetates::Diclofenaces
dc.subject.meshMedical Subject Headings::Chemicals and Drugs::Heterocyclic Compounds::Heterocyclic Compounds, 1-Ring::Azoles::Pyrazoles::Pyrazolones::Aminopyrine::Dipyronees
dc.subject.meshMedical Subject Headings::Chemicals and Drugs::Organic Chemicals::Carboxylic Acids::Acids, Carbocyclic::Benzoic Acids::Aminobenzoic Acids::Anthranilic Acids::Fenamates::Flufenamic Acides
dc.subject.meshMedical Subject Headings::Chemicals and Drugs::Biological Factors::Biological Markers::Genetic Markerses
dc.subject.meshMedical Subject Headings::Chemicals and Drugs::Organic Chemicals::Amines::Biogenic Amines::Biogenic Monoamines::Histaminees
dc.subject.meshMedical Subject Headings::Chemicals and Drugs::Organic Chemicals::Carboxylic Acids::Acids, Carbocyclic::Phenylpropionates::Ibuprofenes
dc.subject.meshMedical Subject Headings::Chemicals and Drugs::Amino Acids, Peptides, and Proteins::Proteins::Blood Proteins::Immunoproteins::Immunoglobulins::Antibodies::Immunoglobulin Isotypes::Immunoglobulin Ees
dc.subject.meshMedical Subject Headings::Chemicals and Drugs::Heterocyclic Compounds::Heterocyclic Compounds, 2-Ring::Indoles::Indomethacines
dc.subject.meshMedical Subject Headings::Chemicals and Drugs::Organic Chemicals::Carboxylic Acids::Acids, Carbocyclic::Phenylpropionates::Ketoprofenes
dc.subject.meshMedical Subject Headings::Analytical, Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Epidemiologic Methods::Statistics as Topic::Models, Statistical::Logistic Modelses
dc.subject.meshMedical Subject Headings::Chemicals and Drugs::Organic Chemicals::Hydrocarbons::Hydrocarbons, Cyclic::Hydrocarbons, Aromatic::Polycyclic Hydrocarbons, Aromatic::Naphthalenes::Naphthaleneacetic Acids::Naproxenes
dc.subject.meshMedical Subject Headings::Chemicals and Drugs::Heterocyclic Compounds::Heterocyclic Compounds, 1-Ring::Azoles::Pyrazoles::Pyrazolones::Phenylbutazone::Oxyphenbutazonees
dc.subject.meshMedical Subject Headings::Chemicals and Drugs::Organic Chemicals::Sulfur Compounds::Thiazines::Piroxicames
dc.subject.meshMedical Subject Headings::Phenomena and Processes::Genetic Phenomena::Genetic Variation::Polymorphism, Genetic::Polymorphism, Single Nucleotidees
dc.subject.meshMedical Subject Headings::Chemicals and Drugs::Heterocyclic Compounds::Heterocyclic Compounds, 1-Ring::Pyridineses
dc.subject.meshMedical Subject Headings::Chemicals and Drugs::Amino Acids, Peptides, and Proteins::Proteins::Membrane Proteins::Receptors, Cell Surface::Receptors, Immunologic::Receptors, Fc::Receptors, IgEes
dc.subject.meshMedical Subject Headings::Chemicals and Drugs::Organic Chemicals::Sulfur Compoundses
dc.titleFCERI and Histamine Metabolism Gene Variability in Selective Responders to NSAIDS.es
dc.typeresearch article
dc.type.hasVersionVoR
dspace.entity.typePublication

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
AmoG_FCERIAndHistamineMetabolism.pdf
Size:
427.44 KB
Format:
Adobe Portable Document Format
Description:
Artículo publicado